Clinical, pharmacology and in vivo studies of QingDai (indigo naturalis) promotes mucosal healing and symptom improvement in ulcerative colitis by regulating the AHR-Th17/Treg pathway

Abstract Qingdai (QD), derived from various plant sources, is commonly used in traditional Chinese medicine for ulcerative colitis (UC) treatment. However, the clinical efficacy and mechanisms of orally administered QD remain unclear. This study aims to evaluate QD’s efficacy in UC treatment and unc...

Full description

Saved in:
Bibliographic Details
Main Authors: Sizhen Gu, Yan Xue, Xiaowen Liu, Yini Tang, Dong Wang, Dongmei Wu, Mingrong Yao, Zehua Xia, Sen Yang, Gan Cai, Shigui Xue, Danbo Dou
Format: Article
Language:English
Published: BMC 2024-11-01
Series:Journal of Inflammation
Subjects:
Online Access:https://doi.org/10.1186/s12950-024-00413-x
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850062317198245888
author Sizhen Gu
Yan Xue
Xiaowen Liu
Yini Tang
Dong Wang
Dongmei Wu
Mingrong Yao
Zehua Xia
Sen Yang
Gan Cai
Shigui Xue
Danbo Dou
author_facet Sizhen Gu
Yan Xue
Xiaowen Liu
Yini Tang
Dong Wang
Dongmei Wu
Mingrong Yao
Zehua Xia
Sen Yang
Gan Cai
Shigui Xue
Danbo Dou
author_sort Sizhen Gu
collection DOAJ
description Abstract Qingdai (QD), derived from various plant sources, is commonly used in traditional Chinese medicine for ulcerative colitis (UC) treatment. However, the clinical efficacy and mechanisms of orally administered QD remain unclear. This study aims to evaluate QD’s efficacy in UC treatment and uncover its active components and mechanisms. A randomized controlled trial compared QD to Adisa, followed by UPLC-Q-TOF/MS and network pharmacology analyses to identify QD’s core components and targets. In vivo experiments on a UC mouse model explored QD’s impact on the AHR-Th17/Treg pathway using PCR, WB, ELISA, and flow cytometry. Results showed QD’s efficacy in UC treatment, with mucosal healing and remission comparable to Adisa. UPLC-Q-TOF/MS identified 16 core components in mouse colon tissue, with network pharmacology revealing 67 targets, potentially involving the IL-17 signaling pathway and Th17 cell differentiation. QD and its components up-regulated AHR, CYP1A1, and Foxp3, while down-regulating RORγt. Additionally, QD modulated pro-inflammatory (IL-6, IL-17 A) and anti-inflammatory (IL-10, TGF-β1) factors, and Treg/Th17 cell ratios in LPMC. Oral QD administration effectively promoted mucosal healing and improved UC symptoms, potentially through AHR-Th17/Treg pathway regulation.
format Article
id doaj-art-e32309fc633d44298f9a141bbd854e63
institution DOAJ
issn 1476-9255
language English
publishDate 2024-11-01
publisher BMC
record_format Article
series Journal of Inflammation
spelling doaj-art-e32309fc633d44298f9a141bbd854e632025-08-20T02:49:56ZengBMCJournal of Inflammation1476-92552024-11-0121111410.1186/s12950-024-00413-xClinical, pharmacology and in vivo studies of QingDai (indigo naturalis) promotes mucosal healing and symptom improvement in ulcerative colitis by regulating the AHR-Th17/Treg pathwaySizhen Gu0Yan Xue1Xiaowen Liu2Yini Tang3Dong Wang4Dongmei Wu5Mingrong Yao6Zehua Xia7Sen Yang8Gan Cai9Shigui Xue10Danbo Dou11Department of Traditional Chinese Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese MedicineDepartment of Traditional Chinese Medicine, Shanghai Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Centre), ChinaDepartment of Traditional Chinese Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese MedicineDepartment of Digestive Endoscopy Center, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese MedicineDepartment of Gastroenterology, The second hospital of Hebei Medical UniversityDepartment of Pathology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese MedicineDepartment of Radiology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese MedicineDepartment of Anorectal, Shuguang Hospital affiliated to Shanghai University of traditional Chinese MedicineDepartment of Clinical Lab, Shuguang Hospital affiliated to Shanghai University of traditional Chinese MedicineDepartment of Gastroenterology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese MedicineDepartment of Digestive Endoscopy Center, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese MedicineDepartment of Traditional Chinese Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese MedicineAbstract Qingdai (QD), derived from various plant sources, is commonly used in traditional Chinese medicine for ulcerative colitis (UC) treatment. However, the clinical efficacy and mechanisms of orally administered QD remain unclear. This study aims to evaluate QD’s efficacy in UC treatment and uncover its active components and mechanisms. A randomized controlled trial compared QD to Adisa, followed by UPLC-Q-TOF/MS and network pharmacology analyses to identify QD’s core components and targets. In vivo experiments on a UC mouse model explored QD’s impact on the AHR-Th17/Treg pathway using PCR, WB, ELISA, and flow cytometry. Results showed QD’s efficacy in UC treatment, with mucosal healing and remission comparable to Adisa. UPLC-Q-TOF/MS identified 16 core components in mouse colon tissue, with network pharmacology revealing 67 targets, potentially involving the IL-17 signaling pathway and Th17 cell differentiation. QD and its components up-regulated AHR, CYP1A1, and Foxp3, while down-regulating RORγt. Additionally, QD modulated pro-inflammatory (IL-6, IL-17 A) and anti-inflammatory (IL-10, TGF-β1) factors, and Treg/Th17 cell ratios in LPMC. Oral QD administration effectively promoted mucosal healing and improved UC symptoms, potentially through AHR-Th17/Treg pathway regulation.https://doi.org/10.1186/s12950-024-00413-xUlcerative ColitisQingdaiClinical efficacyUPLC-Q-TOF-MSAHRTh17/Treg
spellingShingle Sizhen Gu
Yan Xue
Xiaowen Liu
Yini Tang
Dong Wang
Dongmei Wu
Mingrong Yao
Zehua Xia
Sen Yang
Gan Cai
Shigui Xue
Danbo Dou
Clinical, pharmacology and in vivo studies of QingDai (indigo naturalis) promotes mucosal healing and symptom improvement in ulcerative colitis by regulating the AHR-Th17/Treg pathway
Journal of Inflammation
Ulcerative Colitis
Qingdai
Clinical efficacy
UPLC-Q-TOF-MS
AHR
Th17/Treg
title Clinical, pharmacology and in vivo studies of QingDai (indigo naturalis) promotes mucosal healing and symptom improvement in ulcerative colitis by regulating the AHR-Th17/Treg pathway
title_full Clinical, pharmacology and in vivo studies of QingDai (indigo naturalis) promotes mucosal healing and symptom improvement in ulcerative colitis by regulating the AHR-Th17/Treg pathway
title_fullStr Clinical, pharmacology and in vivo studies of QingDai (indigo naturalis) promotes mucosal healing and symptom improvement in ulcerative colitis by regulating the AHR-Th17/Treg pathway
title_full_unstemmed Clinical, pharmacology and in vivo studies of QingDai (indigo naturalis) promotes mucosal healing and symptom improvement in ulcerative colitis by regulating the AHR-Th17/Treg pathway
title_short Clinical, pharmacology and in vivo studies of QingDai (indigo naturalis) promotes mucosal healing and symptom improvement in ulcerative colitis by regulating the AHR-Th17/Treg pathway
title_sort clinical pharmacology and in vivo studies of qingdai indigo naturalis promotes mucosal healing and symptom improvement in ulcerative colitis by regulating the ahr th17 treg pathway
topic Ulcerative Colitis
Qingdai
Clinical efficacy
UPLC-Q-TOF-MS
AHR
Th17/Treg
url https://doi.org/10.1186/s12950-024-00413-x
work_keys_str_mv AT sizhengu clinicalpharmacologyandinvivostudiesofqingdaiindigonaturalispromotesmucosalhealingandsymptomimprovementinulcerativecolitisbyregulatingtheahrth17tregpathway
AT yanxue clinicalpharmacologyandinvivostudiesofqingdaiindigonaturalispromotesmucosalhealingandsymptomimprovementinulcerativecolitisbyregulatingtheahrth17tregpathway
AT xiaowenliu clinicalpharmacologyandinvivostudiesofqingdaiindigonaturalispromotesmucosalhealingandsymptomimprovementinulcerativecolitisbyregulatingtheahrth17tregpathway
AT yinitang clinicalpharmacologyandinvivostudiesofqingdaiindigonaturalispromotesmucosalhealingandsymptomimprovementinulcerativecolitisbyregulatingtheahrth17tregpathway
AT dongwang clinicalpharmacologyandinvivostudiesofqingdaiindigonaturalispromotesmucosalhealingandsymptomimprovementinulcerativecolitisbyregulatingtheahrth17tregpathway
AT dongmeiwu clinicalpharmacologyandinvivostudiesofqingdaiindigonaturalispromotesmucosalhealingandsymptomimprovementinulcerativecolitisbyregulatingtheahrth17tregpathway
AT mingrongyao clinicalpharmacologyandinvivostudiesofqingdaiindigonaturalispromotesmucosalhealingandsymptomimprovementinulcerativecolitisbyregulatingtheahrth17tregpathway
AT zehuaxia clinicalpharmacologyandinvivostudiesofqingdaiindigonaturalispromotesmucosalhealingandsymptomimprovementinulcerativecolitisbyregulatingtheahrth17tregpathway
AT senyang clinicalpharmacologyandinvivostudiesofqingdaiindigonaturalispromotesmucosalhealingandsymptomimprovementinulcerativecolitisbyregulatingtheahrth17tregpathway
AT gancai clinicalpharmacologyandinvivostudiesofqingdaiindigonaturalispromotesmucosalhealingandsymptomimprovementinulcerativecolitisbyregulatingtheahrth17tregpathway
AT shiguixue clinicalpharmacologyandinvivostudiesofqingdaiindigonaturalispromotesmucosalhealingandsymptomimprovementinulcerativecolitisbyregulatingtheahrth17tregpathway
AT danbodou clinicalpharmacologyandinvivostudiesofqingdaiindigonaturalispromotesmucosalhealingandsymptomimprovementinulcerativecolitisbyregulatingtheahrth17tregpathway